NovoSorb™ BTM (Biodegradable Temporizing Matrix)
NovoSorb™ BTM is composed of wound-facing biodegradable foam bonded to a non-biodegradable transparent sealing membrane. Developed for the treatment of full-thickness wounds where the dermal structure has been lost to trauma or surgical debridement.
• Does not contain any sensitizing proteins
• Designed to reduce shrinking and contraction of the wound and scar formation
• Designed to deliver a more aesthetic outcome than currently achieved by immediate split-thickness skin grafting
• Can be applied on surgically debrided wounds
NovoSorb™ BTM (Biodegradable Temporizing Matrix) is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic and vascular ulcers, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscience), trauma wounds (abrasions, lacerations, second-degree burns, and skin tears) and draining wounds.
NovoSorb™ BTM (Biodegradable Temporizing Matrix) application is contraindicated in wounds where necrotic/devitalized tissue is present, such wounds must be surgically debrided to viable tissue pre-application. BTM should not be applied into overtly infected wounds, such wounds should be debrided of non-vital tissue and be topically treated with antimicrobial dressings +/- systematic antibiotics before application is considered. BTM should only be applied into surgically debrided chronic wounds where underlying pathology capable of potentiating the wound has been addressed (e.g. meticulous blood sugar control in diabetic ulceration, compression hosiery/dressings in venous ulceration to combat sustained venous hypertension, etc). BTM should be applied into wounds only after effective hemostasis has been afforded.
The following complications are possible with the use of wound dressing. If any of the following conditions occur, the device should be removed: chronic inflammation, allergic reaction,excessive redness, pain or swelling.
BTM is sterile if the package is unopened and undamaged. Do not use if the package has been perforated or the seal is broken or any other contamination is suspected.
Opened and unused BTM cannot be resterilized and must be discarded.
BTM should not be applied until excessive exudate, bleeding, acute swelling and infection are controlled.
Debridement or excision must be meticulous and remove any remaining necrotic tissue that may cause infection
|Biosynthetic - animal-based|
|Indicated for chronic vascular ulcers||●|
|Indicated for diabetic ulcers||●|
|Indicated for draining wounds||●|
|Indicated for partial- and full-thickness wounds||●|
|Indicated for pressure ulcers||●|
|Indicated for surgical wounds||●|
|Indicated for third-degree burns|
|Indicated for trauma wounds||●|
|Indicated for venous ulcers||●|
|Variety of sizes|
|Educational Material Available|
|Free Samples/Trials Available||●|
|Published Clinical Article Available|
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
Partial- and Full-Thickness Wounds
NovoSorb™ BTM (Biodegradable Temporizing Matrix) is designed to be placed into a newly created wound bed and stapled/sutured to the edge of the wound.
PolyNovo North America LLC is a global medical device company focused on the advancements in regenerative technologies for burn and wound care.